iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Summary
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach
Why It Matters
This announcement reflects ongoing developments in the technology sector that may impact enterprise IT strategy, consumer technology adoption, or industry competitive dynamics.
Note
This summary is generated using AI analysis of the original press release. Always refer to the original source for complete details.